Sources and Guidelines Referenced

The clinical content in this guide is grounded in established international medical society guidelines and peer-reviewed transplant literature, including the American Diabetes Association (ADA) Standards of Care in Diabetes (2024), the Organ Procurement and Transplantation Network (OPTN) / Scientific Registry of Transplant Recipients (SRTR) 2022 Annual Data Report, the International Pancreas & Islet Transplant Association (IPITA) Consensus Guidelines (2021), the American Society of Transplantation (AST) Pancreas Transplantation Practice Guidelines (2020), and peer-reviewed long-term outcome analyses (Gruessner et al., Transplantation Proceedings, 2021; Dean et al., Diabetes Care, 2018).

Pancreas Transplant (select centers): A Comprehensive Patient Guide

1. Definition and Medical Identity

A pancreas transplant is a specialized organ transplantation surgery that involves implanting a healthy donor pancreas into a recipient with severe pancreatic failure. The primary clinical objective is to restore endogenous insulin production and achieve complete independence from exogenous insulin, establishing physiological blood glucose control in patients affected by metabolic complications.

Known medically as whole-organ pancreas transplantation or allogeneic pancreas transplantation, this procedure belongs to the surgical discipline of transplant surgery. Unlike total pancreatectomy, which removes the host organ, a pancreas transplant typically leaves the recipient's native non-functional pancreas in place. The grafted organ performs both endocrine functions (secreting insulin, glucagon, and somatostatin directly into the bloodstream) and exocrine functions (secreting digestive proenzymes into the intestinal tract).

2. The Underlying Condition or Need

Pancreas transplantation addresses absolute insulin deficiency, most commonly caused by autoimmune destruction of pancreatic beta cells in type 1 diabetes mellitus. Without intervention, severe glycemic volatility causes severe hypoglycemia unawareness, progressive vascular damage, end-stage renal failure, diabetic neuropathy, and premature mortality due to microvascular and macrovascular systemic complications.

In patients with long-standing type 1 diabetes mellitus, autoimmune T-cells selectively destroy the insulin-producing beta cells located within the islets of Langerhans. Although exogenous subcutaneous insulin administration is life-saving, it fails to replicate the delicate minute-by-minute glycemic sensing and secretagogue response of an intact organ (ADA Standards of Care 2024). Over time, candidates experience severe glycemic variability, fluctuating rapidly between severe hyperglycemia and life-threatening hypoglycemia.

A critical condition driving isolated pancreas transplantation is hypoglycemia unawareness. Repeated episodes of neuroglycopenia cause a loss of autonomic warning signs (such as tremors, diaphoresis, and tachycardia) when blood glucose drops below normal levels. Patients can unexpectedly lose consciousness or suffer seizures without warning. Furthermore, chronic hyperglycemia inflicts irreversible microvascular damage, precipitating diabetic nephropathy (kidney failure), diabetic retinopathy (vision loss), and peripheral diabetic neuropathy.

3. How the Treatment Works — Mechanism

A donor pancreas functions by supplying active endocrine tissue, specifically the islets of Langerhans containing functional beta cells. Upon vascular connection to the recipient's systemic circulation, these implanted cells automatically sense blood glucose levels and secrete appropriate amounts of insulin and glucagon, directly restoring automatic homeostatic glycemic regulation without manual monitoring.

The mechanism relies on intact vascular and cellular biology. When blood glucose rises following carbohydrate ingestion, glucose molecules enter the grafted beta cells via specialized glucose transporters (GLUT-2). Intracellular glucose metabolism increases the adenosine triphosphate (ATP) to adenosine diphosphate (ADP) ratio, closing ATP-sensitive potassium channels. This depolarizes the cell membrane, triggering calcium influx and immediate exocytosis of stored insulin granules into the circulation (IPITA Guidelines 2021).

Simultaneously, the grafted alpha cells restore physiological glucagon secretion in response to falling blood glucose levels. This restored counter-regulatory capability prevents severe hypoglycemia—a state that exogenous insulin administration cannot replicate. Microvascular protection occurs because homeostatic insulin release maintains systemic glycated hemoglobin (HbA1c) levels within normal reference ranges (typically below 6.0%) without inducing glycemic instability.

4. Types and Variations

Pancreas transplantation is performed in three distinct clinical formats depending on kidney function: simultaneous pancreas-kidney transplant, pancreas after kidney transplant, and pancreas transplant alone. Selection depends on whether the patient has concurrent renal failure, existing renal graft function, or isolated severe metabolic instability without renal insufficiency.

Clinicians categorize whole-organ pancreas transplantation into three major surgical subtypes based on recipient renal status and donor availability:

Surgical variations also exist regarding exocrine drainage management. The primary modern approach is enteric drainage, where the donor duodenal segment is anastomosed to the recipient's jejunum, allowing digestive enzymes to flow naturally into the intestine. Less commonly, bladder drainage is performed, connecting the donor duodenum to the urinary bladder. Bladder drainage allows direct urinary amylase monitoring to assess for early graft rejection, but carries high rates of metabolic acidosis, chemical cystitis, and urethral irritation (AST Guidelines 2020).

5. Who the Treatment Is For — Indications

Pancreas transplantation is indicated for patients with type 1 diabetes experiencing recurrent severe hypoglycemic events, hypoglycemia unawareness, or extreme metabolic instability despite optimized medical management. It is also indicated for individuals with diabetic end-stage renal disease who require concurrent or subsequent renal transplantation to protect graft health.

The specific clinical criteria established by the American Society of Transplantation (AST) and the International Pancreas & Islet Transplant Association (IPITA) include:

• Diagnosis of type 1 diabetes mellitus (or select cases of pancreatectomy-induced absolute insulin deficiency) with documented C-peptide deficiency (< 0.2 nmol/L).
• History of recurrent, severe acute metabolic complications (frequent ketoacidosis, unprovoked severe hypoglycemia requiring third-party assistance).
• Documented hypoglycemia unawareness persistent despite modern continuous glucose monitoring (CGM) and automated insulin delivery (AID) technology.
• Presence of diabetic end-stage renal disease managed with dialysis or approaching renal replacement therapy (estimated Glomerular Filtration Rate [eGFR] < 20 mL/min/1.73m²), qualifying for SPK.
• Severe incapacitation caused by unstable glycemic control that impairs functional independence and quality of life.

6. Who the Treatment Is NOT For — Contraindications

Pancreas transplantation is contraindicated in patients with active systemic infections, advanced coronary artery disease, active malignancy, severe non-compliance, or severe chronic liver disease. Advanced peripheral vascular disease and high surgical risk secondary to severe cardiopulmonary co-morbidities also represent major contraindications to undergoing this intensive procedure.

Absolute and relative contraindications are carefully evaluated during screening to limit surgical mortality and post-operative graft failure:

Absolute Contraindications

• Active, untreated systemic bacterial, viral, or fungal infections.
• Severe, non-revascularizable coronary artery disease or advanced left ventricular dysfunction (ejection fraction < 30%).
• Active or recent malignancy (excluding non-melanoma skin cancer) without an adequate disease-free remission period (typically 2 to 5 years depending on tumor type).
• Documented ongoing non-adherence to medical regimens or severe, untreated psychiatric disorders that impair post-transplant care compliance.
• Active substance abuse (alcohol, illicit drugs, or nicotine).
• Severe, irreversible hepatic cirrhosis.

Relative Contraindications

• Severe iliac artery calcification or peripheral vascular disease that prevents safe microvascular anastomosis.
• Body Mass Index (BMI) > 32–35 kg/m² (associated with high rates of surgical site infection, wound dehiscence, and graft thrombosis).
• Advanced age (typically relative above 55–60 years, evaluated individually based on biological vascular age).
• Active peptic ulcer disease or severe neurogenic bladder refractory to treatment.

7. Alternatives and Clinical Comparison

Alternatives to pancreas transplantation include intensive insulin therapy using automated insulin delivery systems and continuous glucose monitors, as well as donor islet cell transplantation. While insulin systems are non-invasive, they do not restore endogenous feedback loops, and islet transplantation offers lower surgical risk but requires multiple donors.

Patients evaluating therapeutic management for severe type 1 diabetes consider non-surgical, minimally invasive, and whole-organ surgical approaches:

8. Pre-Treatment Phase

The pre-treatment phase involves extensive multidisciplinary evaluation, including cardiovascular risk stratification, immunological matching, viral screening, and psychological assessment. Eligible candidates are placed on a national organ registry, requiring continuous readiness for donor availability while maintaining strict glycemic and physiological optimization during the waiting period.

The formal pre-transplant workup is conducted over several weeks to months in specialized transplant centers. Key diagnostic and preparatory steps include:

• Cardiovascular Evaluation: Coronary angiography or dobutamine stress echocardiography, electrocardiogram (ECG), and carotid duplex ultrasound to screen for silent myocardial ischemia and severe vascular disease common in long-standing diabetes.
• Immunological Profiling: Human Leukocyte Antigen (HLA) typing and Panel Reactive Antibody (PRA) screening to evaluate pre-existing alloantibodies and determine crossmatch compatibility.
• Vascular Mapping: Abdominal and pelvic Computed Tomography (CT) angiography to ensure the iliac arteries and veins are anatomically suitable for vascular anastomoses.
• Infectious Disease Screening: Serologies for Cytomegalovirus (CMV), Epstein-Barr Virus (EBV), Hepatitis B and C, Human Immunodeficiency Virus (HIV), Syphilis, and Tuberculosis (IGRA).
• Multidisciplinary Clearance: Comprehensive consultations with transplant surgeons, nephrologists, endocrinologists, transplant social workers, psychiatrists, and registered dietitians.

Upon clearance, the patient is listed on the national organ procurement network (such as UNOS in the United States or Eurotransplant in Europe). While on the waiting list, candidates must maintain continuous phone access, fast immediately when called for organ offers, undergo periodic blood sampling for PRA updates, and manage blood glucose and blood pressure strictly.

9. The Procedure — Step-by-Step Clinical Detail

Pancreas transplantation involves a lower abdominal incision, vascular connection of donor iliac vessels to recipient iliac arteries and veins, and creation of exocrine drainage into the small intestine or bladder. The procedure typically lasts three to five hours under general anesthesia with continuous hemodynamic monitoring and direct microvascular verification.

The surgical protocol proceeds sequentially through established operational phases:

Phase 1: Organ Receipt and Bench Preparation

The donor pancreas—retrieved from a brain-dead deceased donor along with the donor duodenum and spleen—is brought to the back table in the operating room. Surgical technicians and surgeons inspect the organ, perform splenectomy, and construct a arterial reconstruction (typically utilizing a donor iliac artery Y-graft to join the donor superior mesenteric artery and splenic artery into a single arterial inflow conduit).

Phase 2: Surgical Exposure and Vascular Anastomosis

Under general endotracheal anesthesia, a midline lower abdominal incision is performed. The recipient's right or left common or external iliac artery and vein are mobilized. The donor portal vein is anastomosed end-to-side to the recipient's iliac vein (or, in portal drainage protocols, to a branch of the superior mesenteric vein). The donor arterial Y-graft is anastomosed end-to-side to the recipient's iliac artery.

Phase 3: Reperfusion and Hemostasis

Vascular clamps are removed, re-establishing blood flow to the donor pancreas. The graft rapidly reperfuses, turning pink and demonstrating arterial pulsations. Surgical micro-bleeding is controlled, and native vascular flow is verified using intraoperative Doppler ultrasound.

Phase 4: Exocrine Drainage Construction

To manage the continuous secretion of pancreatic digestive enzymes, the surgeon creates a side-to-side enteric anastomosis between the donor duodenal segment and a loop of the recipient's proximal jejunum (small intestine). Alternatively, in bladder-drained procedures, the duodenal segment is anastomosed to the posterior bladder wall.

Phase 5: Drainage and Closure

Surgical closed-suction drains (such as Jackson-Pratt drains) are positioned adjacent to the graft to monitor for postoperative bleeding or fluid leaks. The abdominal wall is closed in anatomical layers, and sterile dressings are applied.

10. Immediate Post-Procedure Period

The immediate post-procedure period requires intensive care unit monitoring for microvascular perfusion, graft thrombosis, bleeding, and acute metabolic changes. Clinicians continuously evaluate graft function through blood glucose normalization, serum amylase and lipase levels, and Doppler ultrasonography to ensure optimal vascular inflow and outflow during the initial 48 hours.

Following surgery, the patient is transferred directly to the Intensive Care Unit (ICU) or specialized Transplant Step-Down Unit. Key monitoring parameters during the first 24 to 48 hours include:

• Vascular Surveillance: Bedside color Doppler ultrasound is performed at scheduled intervals (e.g., immediately post-op, 6 hours, 12 hours, and 24 hours) to confirm patency of the pancreatic arterial and venous anastomoses, as graft thrombosis represents the leading cause of early technical failure (SRTR 2022).
• Glycemic Dynamics: Intravenous insulin infusions are typically discontinued in the operating room. Blood glucose is measured hourly; immediate normoglycemia (100–140 mg/dL) confirms prompt endocrine graft function.
• Anticoagulation Protocol: Low-dose intravenous heparin or antiplatelet agents (aspirin) are initiated according to protocol to reduce the risk of graft thrombosis without precipitating intra-abdominal hemorrhage.
• Immunosuppressive Induction: High-dose intravenous corticosteroids and induction biological agents (such as anti-thymocyte globulin [ATG] or basiliximab) are administered to prevent hyperacute and early acute cellular rejection.
• Pain Management: Patient-controlled analgesia (PCA) using intravenous opioids manages incisional discomfort while avoiding non-steroidal anti-inflammatory drugs (NSAIDs) due to nephrotoxicity risks.

11. Recovery — Short and Long Term

Recovery involves a ten to fourteen day inpatient stay followed by months of rigorous outpatient surveillance. Patients undergo regular laboratory testing, protocol biopsies, and dosage adjustments of immunosuppressive medications, with full physical activity resuming after eight to twelve weeks while lifelong maintenance antirejection therapy is maintained.

Short-Term Recovery (Weeks 1 to 12)

Patients are discharged from the hospital once oral intake is established, pain is managed with oral medications, surgical drains are removed, and immunosuppressive blood levels (tacrolimus or cyclosporine trough levels) achieve target therapeutic ranges. During the first three months:

• Laboratory monitoring occurs 2 to 3 times weekly, evaluating complete blood counts, renal panel, serum amylase, lipase, fast blood glucose, and trough immunosuppressant levels.
• Strenuous activity, heavy lifting exceeding 10 pounds (4.5 kg), and vigorous exercise are strictly prohibited for 8 to 12 weeks to prevent abdominal incisional hernia formation and vascular graft displacement.
• Prophylactic medications are prescribed to prevent opportunistic infections, typically including trimethoprim-sulfamethoxazole for Pneumocystis jirovecii pneumonia and valganciclovir for Cytomegalovirus (CMV) for 3 to 6 months post-transplant.

Long-Term Recovery (Months 3 and Beyond)

As graft stability is confirmed, clinic visits taper to monthly, then quarterly, and eventually semi-annually. Long-term management focuses on:

• Lifelong Immunosuppression Maintenance: Typically comprising a calcineurin inhibitor (tacrolimus), an antimetabolite (mycophenolate mofetil or enteric-coated mycophenolate sodium), and low-dose maintenance prednisone.
• Protocol Graft Surveillance: Monitoring HbA1c, fasting C-peptide, and urinary amylase (if bladder-drained). Percutaneous ultrasound-guided core needle biopsy of the graft is performed if serum amylase/lipase rises or blood glucose levels deteriorate unexplainedly, assessing for acute or chronic rejection.
• Return to Full Function: Patients typically resume full-time employment, travel, and non-contact exercise within 3 to 6 months post-surgery. Driving can be resumed once abdominal pain resolves and opioid medications are discontinued (usually 4 to 6 weeks).

12. Risks, Side Effects, and Complications

Pancreas transplantation carries significant risks, including graft vascular thrombosis, acute or chronic rejection, pancreatic fistulas, intra-abdominal infections, and bleeding. Long-term complications stem primarily from immunosuppressive medications, which increase susceptibility to opportunistic infections, nephrotoxicity, new-onset post-transplant diabetes, and secondary malignancies over extended follow-up periods.

Complications associated with whole-organ pancreas transplantation are categorized by incidence and severity in clinical literature (Gruessner et al., 2021):

Long-Term Safety Data and Adverse Effects

Long-term survival and graft function are governed by the balance between preventing organ rejection and avoiding immunosuppressive toxicity. Calcineurin inhibitors (tacrolimus, cyclosporine) carry inherent nephrotoxicity risks, necessitating careful trough level titration, particularly in Pancreas Transplant Alone (PTA) recipients with native kidneys. Immunosuppressed patients have a 2- to 4-fold elevated long-term risk of developing secondary malignancies, particularly non-melanoma skin carcinomas and lymphoproliferative disorders (OPTN/SRTR 2022). Annual dermatological exams and age-appropriate cancer screening are mandatory.

13. Lifestyle and Behavioural Considerations

Post-transplant recovery requires lifelong adherence to daily immunosuppression protocols, strict hand hygiene, and routine infection prophylaxis. Patients must follow specific nutritional guidelines, maintain adequate hydration, abstain from tobacco and excessive alcohol, and participate in regular low-impact exercise to optimize cardiovascular health and maintain long-term graft survival.

Nutritional & Dietary Guidelines

Following successful transplantation, patients no longer require diabetic carbohydrate-restricted diets. However, tailored nutrition remains critical:

• Infection Control: Adhere to food safety principles, avoiding unpasteurized dairy, raw or undercooked meats/seafood, and unwashed produce due to immunosuppression-related foodborne infection risks.
• Weight & Glycemic Management: Post-transplant appetite stimulation caused by corticosteroids and resolution of diabetes can cause rapid weight gain. A balanced Mediterranean-style diet rich in lean proteins, whole grains, and fresh vegetables is recommended.
• Hydration: Maintain daily fluid intake of 2.5 to 3.0 liters to maintain renal perfusion and support metabolic waste excretion. Avoid grapefruit and pomegranates, which inhibit cytochrome P450 3A4 enzymes and cause toxic blood elevations of tacrolimus and cyclosporine.

Physical Activity & Habits

• Exercise: Gradually increase walking immediately post-discharge. Progress to moderate cardiovascular exercise (cycling, swimming, jogging) after 8 to 12 weeks. Avoid contact sports (such as football or martial arts) that risk direct traumatic impact to the abdominal graft.
• Substance Cessation: Absolute prohibition of tobacco and nicotine products is essential, as nicotine induces microvascular vasoconstriction and doubles graft failure risks. Alcohol consumption should be strictly minimized or avoided due to hepatic metabolism of immunosuppressive agents.
• Sun Protection: Apply broad-spectrum SPF 50+ sunscreen daily and wear protective clothing to mitigate elevated skin cancer risks secondary to long-term antirejection medications.

14. How Outcomes Are Measured

Pancreas transplant outcomes are evaluated through graft survival rates, patient survival, complete insulin independence, glycated hemoglobin normalization, and resolution of hypoglycemic events. Endocrine function is verified by measuring circulating C-peptide levels, while secondary outcomes monitor the stabilization or attenuation of microvascular diabetic complications over time.

Transplant surgical outcomes are tracked continuously by international registries, such as the Scientific Registry of Transplant Recipients (SRTR) and Eurotransplant:

Primary Clinical Endpoints

• Graft Survival: Defined as complete freedom from exogenous insulin administration, absence of baseline C-peptide loss (> 0.5 ng/mL), and absence of pancreatectomy. According to OPTN/SRTR 2022 data, 1-year graft survival rates are approximately 89–93% for SPK transplants, 83–86% for PAK transplants, and 78–82% for PTA procedures. Ten-year SPK graft survival rates exceed 60–70% in high-volume centers (Gruessner et al., 2021).
• Patient Survival: One-year overall patient survival across all pancreas transplant categories exceeds 95–97%, with 5-year patient survival rates ranging between 88% and 92%.
• Glycemic Normalization: Mean post-transplant HbA1c levels consistently drop to within normal non-diabetic reference ranges (5.0% to 5.7%) without producing hypoglycemic episodes.

Secondary Clinical Endpoints

• Resolution of Hypoglycemia Unawareness: Complete restoration of counter-regulatory autonomic warning symptoms during experimental hypoglycemic clamps within 3 to 6 months post-transplant (Dean et al., 2018).
• Microvascular Stabilization: Stabilization of diabetic retinopathy on dilated funduscopic examination and prevention of recurrent diabetic nephropathy in the co-transplanted or native kidney.

15. Recent Advances and Current Standard of Care

Recent advances in pancreas transplantation include normothermic machine perfusion, refined immunosuppressive regimens with calcineurin inhibitor minimization, laparoscopic donor procurement techniques, and enteric drainage preference. These innovations have reduced early technical failures, decreased acute rejection episodes, and extended long-term graft survival across major international transplant registries.

Over the past decade, several technical and therapeutic innovations have refined the standard of care:

• Ex Vivo Machine Perfusion: Emerging organ preservation technologies utilize oxygenated hypothermic or normothermic machine perfusion for donor pancreases prior to implantation. This mitigates cold ischemia injury, reduces ischemia-reperfusion pancreatitis, and expands the usable donor pool (IPITA Guidelines 2021).
• Targeted Immunosuppressive Regimens: The widespread adoption of lymphocyte depletion induction therapy (using anti-thymocyte globulin) combined with tacrolimus, mycophenolate mofetil, and rapid corticosteroid withdrawal protocols has reduced acute rejection rates to below 15% in the first post-transplant year while minimizing steroid-associated metabolic side effects.
• Routine Enteric Drainage Preference: Surgical consensus has shifted globally toward primary enteric exocrine drainage, reserving bladder drainage for rare high-risk anatomical scenarios. This shift has dramatically decreased post-operative metabolic acidosis, urinary tract complications, and secondary conversion operations.
• Advanced Biomarker Surveillance: Non-invasive monitoring of donor-derived cell-free DNA (dd-cfDNA) in recipient plasma is currently being validated to detect subclinical graft rejection earlier than conventional enzyme rises or invasive needle biopsies.

16. Common Myths and Misconceptions

Widespread misconceptions exist regarding pancreas transplantation, including beliefs that it is routine for all diabetic patients or that rejection is inevitable. Evidence demonstrates that transplantation is reserved for severe metabolic instability or concurrent renal failure, and modern immunosuppression achieves excellent multi-year graft survival rates.

Myth: Pancreas transplantation is a routine treatment option for anyone diagnosed with type 1 or type 2 diabetes.
Reality: Pancreas transplantation is a major surgical procedure reserved specifically for type 1 diabetic patients with severe, uncontrollable metabolic complications, hypoglycemia unawareness, or concurrent end-stage renal disease (ADA Standards of Care 2024). It is rarely performed for type 2 diabetes due to underlying insulin resistance rather than absolute insulin deficiency.

Myth: A pancreas transplant removes the need for all future medical treatment and medications.
Reality: While a successful transplant eliminates the need for exogenous insulin, it requires lifelong adherence to systemic immunosuppressive medications to prevent graft rejection, alongside ongoing medical surveillance for potential medication side effects.

Myth: Islet cell transplantation has rendered whole-organ pancreas transplantation obsolete.
Reality: While islet cell transplantation is less invasive, whole-organ pancreas transplantation currently offers significantly higher long-term insulin independence rates, greater graft durability, and superior functional outcomes in major registry comparisons (SRTR 2022).

Myth: Organ rejection means the transplanted pancreas will immediately fail and must be removed.
Reality: Acute rejection episodes occur in 10–20% of recipients but are typically reversible when detected early through routine laboratory monitoring and treated promptly with high-dose pulse corticosteroids or anti-thymocyte biological agents.

Myth: Receiving a pancreas transplant cures underlying autoimmune disease entirely.
Reality: Transplantation replaces the destroyed endocrine tissue and restores metabolic control, but the recipient's underlying autoimmune system retains the memory of anti-islet antibodies. Continuous immunosuppression is required to prevent both alloimmune organ rejection and recurrent autoimmune destruction of the new beta cells.

Myth: Patients can never exercise or play sports after a pancreas transplant.
Reality: Following an initial 8- to 12-week postoperative healing period, recipients are actively encouraged to engage in regular aerobic exercise and strength training to maintain cardiovascular health, though high-impact contact sports are restricted to protect the abdominal graft.

17. Frequently Asked Questions

What is the main goal of a pancreas transplant?

The primary goal is to restore normal endogenous insulin secretion, establishing biological glycemic control and eliminating dependency on exogenous insulin injections. This restores physiological awareness of falling blood sugar, eliminates life-threatening hypoglycemic episodes, and prevents or halts the progression of microvascular diabetic complications in high-risk patients with severe type 1 diabetes.

How long does a donor pancreas typically last after transplantation?

According to registry data from the Scientific Registry of Transplant Recipients, median graft survival for simultaneous pancreas-kidney (SPK) transplants is 12 to 15 years, with many grafts functioning beyond 20 years. Grafts transplanted alone (PTA) or after a kidney (PAK) have median functional survival rates between 8 and 10 years, governed primarily by rejection prevention and medication adherence.

Is a pancreas transplant performed at the same time as a kidney transplant?

In approximately 75–80% of cases, the pancreas is transplanted simultaneously with a kidney from the same deceased donor in a procedure called Simultaneous Pancreas-Kidney (SPK) transplantation. This combined approach is indicated for patients with type 1 diabetes who also suffer from end-stage renal disease, providing complete freedom from both dialysis and exogenous insulin.

What is the difference between a pancreas transplant and islet cell transplantation?

A whole-organ pancreas transplant is an open abdominal operation that implants the entire intact organ along with its blood vessels and exocrine tissue. Islet cell transplantation is a minimally invasive procedure that isolates insulin-producing islet cells from a donor organ and injects them through a catheter into the recipient's liver portal vein.

Will I need to take anti-rejection medications forever?

Yes. Every pancreas transplant recipient must take immunosuppressive medications daily for the entire life of the functioning graft. Stopping or missing antirejection drugs allows the recipient's immune system to recognize the donor organ as foreign tissue, precipitating acute immune rejection, loss of beta-cell function, graft failure, and return to insulin dependency.

How long is the hospital stay for a pancreas transplant?

The average post-operative hospital stay ranges from 7 to 14 days, assuming no major surgical or medical complications arise. The initial 24 to 48 hours are spent in an intensive care unit for frequent microvascular Doppler ultrasound monitoring, followed by transfer to a specialized transplant ward for mobilization, pain control, and immunosuppression titration.

What are the signs of pancreas graft rejection?

Early graft rejection often produces no noticeable physical symptoms and is detected primarily through rising blood glucose levels or elevated pancreatic enzymes (amylase and lipase) on routine blood work. Advanced rejection may cause graft tenderness or swelling in the lower abdomen, fever, nausea, vomiting, sudden hyperglycemia, and decreased urinary amylase output (in bladder-drained grafts).

Can a person with type 2 diabetes receive a pancreas transplant?

Pancreas transplantation is rarely performed for type 2 diabetes. Type 2 diabetes is primarily characterized by peripheral insulin resistance rather than absolute insulin deficiency due to beta-cell destruction. However, select non-obese patients with type 2 diabetes who demonstrate severe C-peptide depletion and low peripheral insulin resistance may be evaluated on an individual basis at specialized centers.

What happens to my native, non-functioning pancreas during surgery?

Your native pancreas is left undisturbed in its natural anatomical position in the upper abdomen. The donor pancreas is implanted lower in the abdomen (the right or left iliac fossa) and connected to the iliac blood vessels. The native pancreas continues to produce exocrine digestive juices (if present) without interfering with the donor organ's function.

How soon after surgery can I return to work and daily activities?

Most patients can return to light desk work and driving within 4 to 6 weeks post-transplant, provided they are no longer taking prescription opioid pain medications. Jobs requiring heavy physical labor, lifting objects over 10 pounds, or strenuous exertion typically require an 8- to 12-week recovery period to allow the abdominal incision to heal fully.

What dietary restrictions are necessary after a pancreas transplant?

While patients no longer need a strict diabetic diet, they must observe food safety rules to avoid infections caused by immunosuppression. This includes avoiding raw seafood, unpasteurized dairy, and undercooked meats. Additionally, patients must completely avoid grapefruit, pomegranates, and their juices, as these interact dangerously with calcineurin inhibitor medications like tacrolimus.

What happens if the transplanted pancreas fails?

If a transplanted pancreas experiences chronic rejection or vascular loss, it gradually loses its ability to produce insulin. The patient will resume subcutaneous insulin therapy or continuous glucose monitoring to manage blood sugar. In most cases, the non-functioning graft can remain safely inside the abdomen unless it causes pain, infection, or severe inflammation, in which case surgical pancreatectomy is performed.